Skip to main content

Advertisement

SpringerLink
Log in

First-Line Biologics or Small Molecules in Inflammatory Bowel Disease: a Practical Guide for the Clinician

  • Inflammatory Bowel Disease (M Regueiro, Section Editor)
  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Treating moderate-to-severe inflammatory bowel disease has become increasingly complex as the array of available biologics increases. Moreover, tofacitinib, the first small molecule approved for IBD, is available for use in ulcerative colitis. Choosing the right biologic, for the right patient, at the right time, can be a confusing and daunting task for clinicians.

Recent Findings

In this review, we summarize the evidence for first-line use of the available biologics by disease state. Special circumstances for consideration including rapidity of action, safety, comparative effectiveness, postoperative Crohn’s disease, fertility and pregnancy, and extraintestinal manifestations are discussed.

Summary

In the moderate-to-severe UC patient, vedolizumab and infliximab are preferred first-line options. In the moderate-to-severe CD patient with a penetrating phenotype or with multiple EIMs, infliximab or adalimumab are the preferred first-line agents. In the moderate-to-severe CD patient with an inflammatory phenotype, anti-TNF, vedolizumab, and ustekinumab are all reasonable options.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9. https://doi.org/10.1016/S0140-6736(02)08512-4.

    Article  PubMed  CAS  Google Scholar 

  2. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323–33; quiz 591. https://doi.org/10.1053/j.gastro.2005.11.030.

    Article  PubMed  CAS  Google Scholar 

  3. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65. https://doi.org/10.1053/j.gastro.2006.11.041.

    Article  PubMed  CAS  Google Scholar 

  4. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56(9):1232–9. https://doi.org/10.1136/gut.2006.106781.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med. 2007;357(3):228–38. https://doi.org/10.1056/NEJMoa067594.

    Article  PubMed  CAS  Google Scholar 

  6. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med. 2007;357(3):239–50. https://doi.org/10.1056/NEJMoa062897.

    Article  PubMed  CAS  Google Scholar 

  7. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340(18):1398–405. https://doi.org/10.1056/NEJM199905063401804.

    Article  PubMed  CAS  Google Scholar 

  8. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–76. https://doi.org/10.1056/NEJMoa050516.

    Article  PubMed  CAS  Google Scholar 

  9. Reinisch W, Sandborn WJ, Hommes DW, D’Haens G, Hanauer S, Schreiber S, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60(6):780–7. https://doi.org/10.1136/gut.2010.221127.

    Article  PubMed  CAS  Google Scholar 

  10. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):85–95; quiz e14–5. https://doi.org/10.1053/j.gastro.2013.05.048.

    Article  PubMed  CAS  Google Scholar 

  11. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):96–109 e1. https://doi.org/10.1053/j.gastro.2013.06.010.

    Article  PubMed  CAS  Google Scholar 

  12. Sands BE, Blank MA, Patel K, van Deventer SJ, Study AI. Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol. 2004;2(10):912–20.

    Article  CAS  Google Scholar 

  13. Berg DR, Colombel JF, Ungaro R. The role of early biologic therapy in inflammatory bowel disease. Inflamm Bowel Dis. 2019. https://doi.org/10.1093/ibd/izz059.

    Article  Google Scholar 

  14. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–95. https://doi.org/10.1056/NEJMoa0904492.

    Article  PubMed  CAS  Google Scholar 

  15. Papamichael K, Vogelzang EH, Lambert J, Wolbink G, Cheifetz AS. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases. Expert Rev Clin Immunol. 2019;15(8):837–48. https://doi.org/10.1080/1744666X.2019.1630273.

    Article  PubMed  CAS  Google Scholar 

  16. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–21. https://doi.org/10.1056/NEJMoa1215739.

    Article  PubMed  CAS  Google Scholar 

  17. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710. https://doi.org/10.1056/NEJMoa1215734.

    Article  PubMed  CAS  Google Scholar 

  18. Mosli MH, MacDonald JK, Bickston SJ, Behm BW, Tsoulis DJ, Cheng J, et al. Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis. Inflamm Bowel Dis. 2015;21(5):1151–9. https://doi.org/10.1097/MIB.0000000000000396.

    Article  PubMed  Google Scholar 

  19. Engel T, Ungar B, Yung DE, Ben-Horin S, Eliakim R, Kopylov U. Vedolizumab in IBD-lessons from real-world experience; a systematic review and pooled analysis. J Crohns Colitis. 2018;12(2):245–57. https://doi.org/10.1093/ecco-jcc/jjx143.

    Article  PubMed  Google Scholar 

  20. Amiot A, Grimaud JC, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, et al. Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2016;14(11):1593–601 e2. https://doi.org/10.1016/j.cgh.2016.02.016.

    Article  PubMed  CAS  Google Scholar 

  21. Vivio EE, Kanuri N, Gilbertsen JJ, Monroe K, Dey N, Chen CH, et al. Vedolizumab effectiveness and safety over the first year of use in an IBD clinical practice. J Crohns Colitis. 2016;10(4):402–9. https://doi.org/10.1093/ecco-jcc/jjv226.

    Article  PubMed  Google Scholar 

  22. Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, et al. Vedolizumab for ulcerative colitis: treatment outcomes from the VICTORY consortium. Am J Gastroenterol. 2018;113(9):1345. https://doi.org/10.1038/s41395-018-0162-0.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. •• Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Toruner M, et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381(13):1215–26. https://doi.org/10.1056/NEJMoa1905725 This is the first head to head study performed comparing 2 biologic therapies, vedolizumab and adalimumab, in moderate to severe ulcerative colitis.

    Article  PubMed  CAS  Google Scholar 

  24. Dulai PS, Singh S, Jiang X, Peerani F, Narula N, Chaudrey K, et al. The real-world effectiveness and safety of vedolizumab or moderate-severe Crohn’s disease: results from the US VICTORY consortium. Am J Gastroenterol. 2016;111(8):1147–55. https://doi.org/10.1038/ajg.2016.236.

    Article  PubMed  CAS  Google Scholar 

  25. Danese S, Sands B, O’Brien C, Zhang H, Johanns J, Sloan S, et al. Efficacy and safety of ustekinumab through week 16 in patients with moderate to severe ulcerative colitis randomized to ustekinumab: results from the UNIFI induction trial. Digest Dis Weekly. 2019:Tu1739.

  26. Sands BE, Sandborn WJ, Panaccione R, O’Brien CD, Zhang H, Johanns J, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201–14. https://doi.org/10.1056/NEJMoa1900750.

    Article  PubMed  CAS  Google Scholar 

  27. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375(20):1946–60. https://doi.org/10.1056/NEJMoa1602773.

    Article  PubMed  CAS  Google Scholar 

  28. Pugliese D, Daperno M, Fiorino G, Savarino E, Mosso E, Biancone L, et al. Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: an IG-IBD study. Dig Liver Dis. 2019;51(7):972–7. https://doi.org/10.1016/j.dld.2019.03.007.

    Article  PubMed  CAS  Google Scholar 

  29. Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford). 2014;53(10):1872–85. https://doi.org/10.1093/rheumatology/keu172.

    Article  CAS  Google Scholar 

  30. Gisbert JP, Chaparro M. Ustekinumab to treat Crohn’s disease. Gastroenterol Hepatol. 2017;40(10):688–98. https://doi.org/10.1016/j.gastrohep.2017.08.006.

    Article  PubMed  Google Scholar 

  31. Sandborn WJ, Su C, Sands BE, D’Haens GR, Vermeire S, Schreiber S, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723–36. https://doi.org/10.1056/NEJMoa1606910.

    Article  PubMed  CAS  Google Scholar 

  32. Tofacitinib [package insert] New York, NY: Pfizer; 2019.

  33. Ha C, Ullman TA, Siegel CA, Kornbluth A. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol. 2012;10(9):1002–7; quiz e78. https://doi.org/10.1016/j.cgh.2012.02.004.

    Article  PubMed  Google Scholar 

  34. Singh S, Proudfoot JA, Dulai PS, Xu R, Feagan BG, Sandborn WJ, et al. Efficacy and speed of induction of remission of infliximab vs golimumab for patients with ulcerative colitis, based on data from clinical trials. Clin Gastroenterol Hepatol. 2019. https://doi.org/10.1016/j.cgh.2019.05.019.

    PubMed  Google Scholar 

  35. Narula N, Marshall JK, Colombel JF, Leontiadis GI, Williams JG, Muqtadir Z, et al. Systematic review and meta-analysis: infliximab or cyclosporine as rescue therapy in patients with severe ulcerative colitis refractory to steroids. Am J Gastroenterol. 2016;111(4):477–91. https://doi.org/10.1038/ajg.2016.7.

    Article  PubMed  CAS  Google Scholar 

  36. Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128(7):1805–11. https://doi.org/10.1053/j.gastro.2005.03.003.

    Article  PubMed  CAS  Google Scholar 

  37. Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380(9857):1909–15. https://doi.org/10.1016/S0140-6736(12)61084-8.

    Article  PubMed  CAS  Google Scholar 

  38. Feagan BG, Lasch K, Lissoos T, Cao C, Wojtowicz AM, Khalid JM, et al. Rapid response to vedolizumab therapy in biologic-naive patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17(1):130–8 e7. https://doi.org/10.1016/j.cgh.2018.05.026.

    Article  PubMed  CAS  Google Scholar 

  39. Sands BE, Sandborn WJ, Van Assche G, Lukas M, Xu J, James A, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease in patients naive to or who have failed tumor necrosis factor antagonist therapy. Inflamm Bowel Dis. 2017;23(1):97–106. https://doi.org/10.1097/MIB.0000000000000979.

    Article  PubMed  Google Scholar 

  40. Hanauer S, Panaccione R, Danese S, Cheifetz A, Reinisch W, Higgins PDR, et al. Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2019;17(1):139–47. https://doi.org/10.1016/j.cgh.2018.07.009.

    Article  PubMed  CAS  Google Scholar 

  41. Berinstein JA, Steiner CA, Regal RE, Allen JI, Kinnucan JAR, Stidham RW, et al. Efficacy of induction therapy with high-intensity tofacitinib in 4 patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2019;17(5):988–90 e1. https://doi.org/10.1016/j.cgh.2018.11.022.

    Article  PubMed  Google Scholar 

  42. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Safdi M, Popp JW Jr, et al. Infliximab for Crohn’s disease: more than 13 years of real-world experience. Inflamm Bowel Dis. 2018;24(3):490–501. https://doi.org/10.1093/ibd/izx072.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7(8):874–81. https://doi.org/10.1016/j.cgh.2009.01.004.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  44. •• Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D’Haens G, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2017;66(5):839–51. https://doi.org/10.1136/gutjnl-2015-311079 This was a pooled safety analysis of all randomized controlled trials with vedolizumab showing lower rates of adverse and serious adverse events with this therapy compated with placebo.

    Article  PubMed  CAS  Google Scholar 

  45. Meserve J, Aniwan S, Koliani-Pace JL, Shashi P, Weiss A, Faleck D, et al. Retrospective analysis of safety of vedolizumab in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17(8):1533–40 e2. https://doi.org/10.1016/j.cgh.2018.09.035.

    Article  PubMed  CAS  Google Scholar 

  46. Bye WA, Jairath V, Travis SPL. Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2017;46(1):3–15. https://doi.org/10.1111/apt.14075.

    Article  PubMed  CAS  Google Scholar 

  47. Papp K, Gottlieb AB, Naldi L, Pariser D, Ho V, Goyal K, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol. 2015;14(7):706–14.

    PubMed  CAS  Google Scholar 

  48. Sands BE, Taub PR, Armuzzi A, Friedman GS, Moscariello M, Lawendy N, et al. Tofacitinib treatment is associated with modest and reversible increases in serum lipids in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2019. https://doi.org/10.1016/j.cgh.2019.04.059.

    Article  CAS  Google Scholar 

  49. Winthrop KL, Melmed GY, Vermeire S, Long MD, Chan G, Pedersen RD, et al. Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis. 2018;24(10):2258–65. https://doi.org/10.1093/ibd/izy131.

    Article  PubMed  PubMed Central  Google Scholar 

  50. •• Drug Safety Communication. Food and Drug Administration. Available at https://www.fda.gov/media/120485/download. Accessed September 9, 2019. This communication from the FDA reported increased risk of pulmonary embolism and mortality in rheumatoid arthritis pateints over the age of 50 with at least one cardiac risk factor on tofacitinib 10mg twice daily.

  51. Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47(2):162–75. https://doi.org/10.1111/apt.14422.

    Article  PubMed  CAS  Google Scholar 

  52. Hazlewood GS, Rezaie A, Borman M, Panaccione R, Ghosh S, Seow CH, et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn’s disease: a network meta-analysis. Gastroenterology. 2015;148(2):344–54 e5; quiz e14–5. https://doi.org/10.1053/j.gastro.2014.10.011.

    Article  PubMed  CAS  Google Scholar 

  53. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113(4):481–517. https://doi.org/10.1038/ajg.2018.27.

    Article  PubMed  Google Scholar 

  54. Frolkis AD, Lipton DS, Fiest KM, Negron ME, Dykeman J, de Bruyn J, et al. Cumulative incidence of second intestinal resection in Crohn’s disease: a systematic review and meta-analysis of population-based studies. Am J Gastroenterol. 2014;109(11):1739–48. https://doi.org/10.1038/ajg.2014.297.

    Article  PubMed  Google Scholar 

  55. Nguyen GC, Loftus EV Jr, Hirano I, Falck-Ytter Y, Singh S, Sultan S, et al. American Gastroenterological Association Institute guideline on the management of Crohn’s disease after surgical resection. Gastroenterology. 2017;152(1):271–5. https://doi.org/10.1053/j.gastro.2016.10.038.

    Article  PubMed  Google Scholar 

  56. Singh S, Garg SK, Pardi DS, Wang Z, Murad MH, Loftus EV Jr. Comparative efficacy of pharmacologic interventions in preventing relapse of Crohn’s disease after surgery: a systematic review and network meta-analysis. Gastroenterology. 2015;148(1):64–76 e2; quiz e14. https://doi.org/10.1053/j.gastro.2014.09.031.

    Article  PubMed  CAS  Google Scholar 

  57. •• Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, et al. Infliximab reduces endoscopic, but not clinical, recurrence of Crohn’s disease after ileocolonic resection. Gastroenterology. 2016;150(7):1568–78. https://doi.org/10.1053/j.gastro.2016.02.072 In this multicenter randomized controlled trial, infliximab was showed to decreased endoscopic recurrence of CD after resection.

    Article  PubMed  CAS  Google Scholar 

  58. Regueiro M, Kip KE, Baidoo L, Swoger JM, Schraut W. Postoperative therapy with infliximab prevents long-term Crohn’s disease recurrence. Clin Gastroenterol Hepatol. 2014;12(9):1494–502 e1. https://doi.org/10.1016/j.cgh.2013.12.035.

    Article  PubMed  CAS  Google Scholar 

  59. De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, et al. Crohn’s disease management after intestinal resection: a randomised trial. Lancet. 2015;385(9976):1406–17. https://doi.org/10.1016/S0140-6736(14)61908-5.

    Article  PubMed  Google Scholar 

  60. De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, et al. Efficacy of thiopurines and adalimumab in preventing Crohn’s disease recurrence in high-risk patients-a POCER study analysis. Aliment Pharmacol Ther. 2015;42(7):867–79. https://doi.org/10.1111/apt.13353.

    Article  PubMed  CAS  Google Scholar 

  61. Lopez-Sanroman A, Vera-Mendoza I, Domenech E, Taxonera C, Vega Ruiz V, Marin-Jimenez I, et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. J Crohns Colitis. 2017;11(11):1293–301. https://doi.org/10.1093/ecco-jcc/jjx051.

    Article  PubMed  Google Scholar 

  62. Yamada A, Komaki Y, Patel N, Komaki F, Pekow J, Dalal S, et al. The use of vedolizumab in preventing postoperative recurrence of Crohn’s disease. Inflamm Bowel Dis. 2018;24(3):502–9. https://doi.org/10.1093/ibd/izx054.

    Article  PubMed  Google Scholar 

  63. Mahadevan U, Robinson C, Bernasko N, Boland B, Chambers C, Dubinsky M, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group. Gastroenterology. 2019;156(5):1508–24. https://doi.org/10.1053/j.gastro.2018.12.022.

    Article  PubMed  Google Scholar 

  64. Abhyankar A, Ham M, Moss AC. Meta-analysis: the impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38(5):460–6. https://doi.org/10.1111/apt.12417.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  65. Mahadevan U, McConnell RA, Chambers CD. Drug safety and risk of adverse outcomes for pregnant patients with inflammatory bowel disease. Gastroenterology. 2017;152(2):451–62 e2. https://doi.org/10.1053/j.gastro.2016.10.013.

    Article  PubMed  Google Scholar 

  66. Luu M, Benzenine E, Doret M, Michiels C, Barkun A, Degand T, et al. Continuous anti-TNFalpha use throughout pregnancy: possible complications for the mother but not for the fetus. A retrospective cohort on the French National Health Insurance Database (EVASION). Am J Gastroenterol. 2018;113(11):1669–77. https://doi.org/10.1038/s41395-018-0176-7.

    Article  PubMed  CAS  Google Scholar 

  67. Mahadevan U. PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology. 2012;142(S–149).

    Article  Google Scholar 

  68. Bar-Gil Shitrit A, Ben Ya’acov A, Livovsky DM, Cuker T, Farkash R, Hoyda A, et al. Exposure to vedolizumab in IBD pregnant women appears of low risk for mother and neonate: a first prospective comparison study. Am J Gastroenterol. 2019;114(7):1172–5. https://doi.org/10.14309/ajg.0000000000000186.

    Article  PubMed  Google Scholar 

  69. Moens A, van Hoeve K, Humblet E, Rahier JF, Bossuyt P, Dewit S, et al. Outcome of pregnancies in female patients with inflammatory bowel diseases treated with vedolizumab. J Crohns Colitis. 2019;13(1):12–8. https://doi.org/10.1093/ecco-jcc/jjy142.

    Article  PubMed  Google Scholar 

  70. Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol. 2005;11(46):7227–36. https://doi.org/10.3748/wjg.v11.i46.7227.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96(4):1116–22. https://doi.org/10.1111/j.1572-0241.2001.03756.x.

    Article  PubMed  CAS  Google Scholar 

  72. Feagan BG, Sandborn WJ, Colombel JF, Byrne SO, Khalid JM, Kempf C, et al. Incidence of arthritis/arthralgia in inflammatory bowel disease with long-term vedolizumab treatment: post hoc analyses of the GEMINI trials. J Crohns Colitis. 2019;13(1):50–7. https://doi.org/10.1093/ecco-jcc/jjy125.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Inflammatory Bowel Disease Center, Division of Gastroenterology, NYU Langone Health, 240 East 38th Street, 23rd Floor, New York, NY, 10016, USA

    Shannon Chang & David Hudesman

Authors
  1. Shannon Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Hudesman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Hudesman.

Ethics declarations

Conflict of Interest

David Hudesman is a consultant for Abbvie, Janssen, Salix, Takeda, and Pfizer.

Shannon Chang is a consultant for Takeda, Oshi Health, and Pfizer.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Inflammatory Bowel Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chang, S., Hudesman, D. First-Line Biologics or Small Molecules in Inflammatory Bowel Disease: a Practical Guide for the Clinician. Curr Gastroenterol Rep 22, 7 (2020). https://doi.org/10.1007/s11894-020-0745-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11894-020-0745-y

Keywords

Search

Navigation